LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...

Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of ...

At close: November 8 at 4:00 PM EST ...

Featured here, the Balance Sheet for Vivos Therapeutics Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 ...

After hours: 8 November at 19:58 GMT-5 ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report released on Monday. The brokerage set a “hold” rating on the stock.

In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $43.00. The company’s shares closed ...

Clairvest's book value was $1,196.9 million or $84.06 per share as at September 30, 2024, compared with $1,186.2 million or $81.02 per share as at June 30, 2024. For the quarter ended September 30, ...

Atossa Therapeutics focuses on developing endoxifen for hormone receptor-positive breast cancer, with promising early-stage trial results but lacks definitive proof of efficacy. The company has ...